Results 11 to 20 of about 5,953 (226)

Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan [PDF]

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 11, November 2025.
ABSTRACT This study examines the impact of hepatitis C virus (HCV) eradication through sofosbuvir/velpatasvir (SOF/VEL) treatment on glycated hemoglobin (HbA1c) levels in patients with chronic hepatitis C and type 2 diabetes mellitus (T2DM). Utilizing data from the Taiwan HCV Registry, a retrospective analysis was conducted on 2180 patients who met the
Szu‐Jen Wang, Te‐Sheng Chang, Gin‐Ho Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Jong Bair, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yuan Hsieh, Tzong‐Hsi Lee, Pei‐Lun Lee, Wen‐Chih Wu, Chih‐Lin Lin, Wei‐Wen Su, Sheng‐Shun Yang, Chia‐Chi Wang, Jui‐Ting Hu, Lein‐Ray Mo, Chun‐Ting Chen, Yi‐Hsiang Huang, Chun‐Chao Chang, Chia‐Sheng Huang, Guei‐Ying Chen, Chien‐Neng Kao, Chi‐Ming Tai, Chun‐Jen Liu, Mei‐Hsuan Lee, Pei‐Chien Tsai, Shu‐Chi Wang, Chia‐Yen Dai, Jia‐Horng Kao, Han‐Chieh Lin, Wan‐Long Chuang, Kuo‐Chih Tseng, Chi‐Yi Chen, Chung‐Feng Huang, Ming‐Lung Yu, Chung‐Feng Huang, Chung‐Feng Huang, Ming‐Lung Yu   +46 more
openalex   +2 more sources

EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN HEMODIALYSIS PATIENTS SUFFERING WITH HEPATITIS C INFECTION

Journal of University Medical & Dental College, 2021
BACKGROUND & OBJECTIVE: There is scantiness of evidence-based knowledge of anti-viral therapy with sofosbuvir (SOF) and velpatasvir (VLP) in patients on maintenance haemodialysis.
Yasir Mehmood, Muhammad Imran Ashraf , Khadija Mastoor, Adnan Afzal , Zafar Latif Awan   +4 more
doaj   +3 more sources

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 2 approved]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +2 more sources

Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children [PDF]

Pediatria Polska
Sofosbuvir/velpatasvir (SOF/VEL) is a safe and effective regimen used for the treatment of chronic hepatitis C. The standard treatment duration is 12 weeks. There are no data available to support the shortened treatment.
Maria Pokorska-Śpiewak, Anna Dobrzeniecka, Magdalena Marczyńska   +2 more
doaj   +2 more sources

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]

J Viral Hepat
ABSTRACT Direct‐acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype‐specific to pan‐genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines.
Luong CL, Ellett LK, Pratt N, Staff K, Janetzki J.   +4 more
europepmc   +2 more sources

Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) micro‐elimination faces challenges from fragmented care pathways, particularly in high‐prevalence regions with complex genotypes and socioeconomic barriers. This study evaluated a simplified ‘Test and Treat’ (TNT) strategy to enhance in‐hospital HCV micro‐elimination by reducing delays and improving linkage to care ...
You C, Diao Y, Tang J, Tang J, Deng W, Zheng C, Liao D, Song D, Wang J, Pu Y.   +9 more
europepmc   +2 more sources

Structure-activity relationships of fluorene compounds inhibiting HCV variants [PDF]

, 2020
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths ...
Gadhe, Changdev G., JANG, SUNG KEY, Keum, Gyochang, Kim, Byeong Moon, Kim, Hee Sun, Kohara, Michinori, Lee, Jae Seung, Moon, Heejo, Mun, Jaegon, Pae, Ae Nim, You, Youngsu   +10 more
core   +1 more source

Molecular docking analysis of peptide-based antiviral agents against SARS-CoV-2 main protease: an approach towards drug repurposing

Exploration of Medicine, 2023
Aim: Utilizing the therapeutic potentials of previously approved medications against a new target or pharmacological response is known as drug repurposing.
Abhishek Chaurasiya, Abhimannu Shome, Pooja A. Chawla   +2 more
doaj   +1 more source

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

Frontiers in Pharmacology, 2020
BackgroundDirect-acting antivirals (DAAs) therapeutic regimens are highly effective against chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) respond in a suboptimal way.
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor   +5 more
doaj   +1 more source

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2023
Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Mohammad Ashraf Bhat, Aadil Nabi Mir, Manzoor Ahmad Parry, Irshad Ahmad Parray   +3 more
doaj   +1 more source